Evidence map›Paper›PMID 35411258›Full record

ArticlePeerJ2022

Study on the mechanism of Danshen-Guizhi drug pair in the treatment of ovarian cancer based on network pharmacology and

Chongzhen Qin, Menglin Wu, Xinru Wang, Wenda Zhang, Guangzhao Qi, Na-Yi Wu, Xiaoting Liu, Yaoyao Lu, Jingmin Zhang, Yuna Chai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Chongzhen Qin *The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Menglin Wu *The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xinru WangThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wenda ZhangThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guangzhao QiThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Na-Yi WuHunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Xiaoting LiuThe Second People's Hospital of Hunan Province, Changsha, China.
Yaoyao LuThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jingmin ZhangThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuna ChaiThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNCentral South University · CNSecond People Hospital of Hunan · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our study aims to explore the active components and mechanisms of the Danshen-Guizhi drug pair in treating ovarian cancer by network pharmacology and

Indexed as

Ovarian NeoplasmsSalvia miltiorrhizaAbietanesCyclooxygenase 2FemaleHumansMolecular Docking SimulationNetwork PharmacologyPhosphatidylinositol 3-KinasesAbietanesCyclooxygenase 2Phosphatidylinositol 3-KinasestanshinoneCore targetsDanshenGuizhiMolecular dockingNetwork pharmacologyOvarian cancer

Identifiers

PMID35411258
PMCPMC8994495
OpenAlexW4225906335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.